ArticleCureus2024
Clinicopathological Study of Mucormycosis at Varied Sites During the COVID-19 Pandemic.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucormycosis, also known as black fungus, is a rare but serious fungal infection caused by mucor that belongs to Zygomycotic species. Mucor is characterized by non-septate, irregularly wide hyphae with right-angle branching. Mucor can infect different systems of the body and manifest differently depending on the location of the infection, which includes pulmonary, gastrointestinal, rhino-cerebral, and cutaneous.
aimThe study aims to analyze the incidence, clinical history, and microscopic features associated with mucormycosis in the COVID-19 pandemic at our institute. MATERIALS AND
methodsThis is a prospective study conducted in the Department of Pathology for three years from March 2020 to April 2022. The samples were collected from different clinical departments mostly from Surgery and Radiology. These samples were fixed in 10% formalin, processed, stained with hematoxylin and eosin (H&E) and were analysed.
resultsA total of 69 cases were included in the study. The age range was 25-80 years and male preponderance was seen with an M:F ratio of 2.6:1. Diabetes was the most common risk factor seen in 53 (77%) cases followed by post-COVID-19 status in 49 (71%) cases. The most common site was paranasal sinuses (58, 84%) followed by orbit (eight, 11%) and two (2.8%) cases each of lung and bone. Fifty (72.4%) cases showed necrosis and 10 (14.5%) cases showed granulomatous inflammation. Angioinvasion was seen in 27 (39%) cases, bony invasion was seen in 26 (37.6%) cases and perineural invasion was seen in one (1.4%) case. We had three (4.3%) cases of mixed fungal infection (mucor and Aspergillus).
conclusionThis study describes the clinical site of presentation and histopathological features of mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.